Compare Charles River Laboratories Intl. Inc (CRL) vs Five9 Inc (FIVN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Five9 Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $283 (market cap $13.58B), while Five9 Inc trades at $33.65 (market cap $2.33B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 5.8× Five9 Inc's market cap. Which is the better fit depends on your goals.
| CRL | FIVN | |
|---|---|---|
Market Cap | $13.58B | $2.33B |
Sector | Health | Technology |
52-Week High | $284.37 | $34.48 |
52-Week Low | $145.57 | $13.61 |
Enterprise Value | $16.41B | $2.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $281.27, near its 52-week high, with a slight 0.26% decline. The stock shows bullish technical signals, including strong moving averages, despite overbought RSI readings. Recent Q2 2026 earnings beat estimates with EPS of $3.02 versus $2.74 expected, and the company raised full-year guidance, reflecting improved biotech demand. However, fundamentals reveal challenges, with a negative net income margin of -5.96% and elevated P/E ratio of 684.85, indicating high valuation relative to profitability.
Outlook: CRL benefits from positive analyst sentiment (72% buy ratings) and institutional accumulation, but risks include profitability pressures, high debt, and reliance on biotech sector health. The consensus price target of $277.29 suggests limited upside, urging caution despite operational improvements.
FIVN trades at $33.80, up 3.59% today, near its 52-week high of $34.58. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for three consecutive quarters. Revenue growth is accelerating, with 2025 revenue reaching $1.15 billion and net income turning positive at $39.42 million, marking a significant improvement from prior losses. Recent management appointments and AI-driven subscription growth are positive catalysts.
The outlook is positive given earnings momentum and analyst support, but risks include high valuation multiples, ongoing legal scrutiny, and dependence on competitive AI adoption. With 61% of analysts rating it a Buy and a consensus target of $32.67, near-term upside appears limited, but execution on guidance could drive further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Five9 Inc
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →
